Key Insights

Highlights

Success Rate

69% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 77/100

Termination Rate

21.1%

4 terminated out of 19 trials

Success Rate

69.2%

-17.3% vs benchmark

Late-Stage Pipeline

11%

2 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed with results

Key Signals

3 with results69% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (6)
P 1 (4)
P 2 (3)
P 3 (2)

Trial Status

Completed9
Terminated4
Unknown2
Recruiting2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

69.2%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT07099898Phase 3RecruitingPrimary

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

NCT04699188Phase 1Active Not Recruiting

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05857995Not ApplicableRecruiting

Precision Lung Cancer Survivorship Care Intervention

NCT02549638Terminated

Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma

NCT04892342Phase 1Completed

Study of ESG401 in Adults With Solid Tumors

NCT05011890Not ApplicableCompleted

Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®

NCT02673021Not ApplicableTerminated

MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

NCT01860898Not ApplicableCompleted

A Phase I Study of iPS Cell Generation From Patients With COPD

NCT02410603Completed

Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer

NCT03603652Not ApplicableTerminated

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

NCT03713099Not ApplicableWithdrawn

NEUWAVE Flexible Probe Study #2

NCT02115958Phase 1CompletedPrimary

The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine

NCT02370303Completed

A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System

NCT02084823Phase 1CompletedPrimary

Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells

NCT00284141Phase 2Completed

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

NCT01131429Phase 2UnknownPrimary

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

NCT00935571Unknown

Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia

NCT00290017Phase 3Terminated

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00042679Phase 2Completed

A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.

Showing all 19 trials

Research Network

Activity Timeline